AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06553924
Drug: Macitentan and Tadalafil film-coated tablets
RxNorm normalized name: macitentan and tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Trial: NCT05397886
Drug: Remimazolam Besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.
Trial: NCT05397886
Drug: Flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
Trial: NCT05397886
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
Trial: NCT04820205
Drug: Intranasal dexmedetomidine and ketamine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to increase the success rate of adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
Trial: NCT04820205
Drug: Oral chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate (50mg/kg) administration to induce adequate pediatric procedural sedation (pediatric sedation state scale = 1,2,3)
Trial: NCT05491057
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib standard dose 240 mg once daily for 1 year
Trial: NCT06549855
Drug: Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks~2. MA, 320mg/MPA, 500mg, po, once a day
Trial: NCT04891991
Drug: Intravitreal infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.
Trial: NCT05744115
Drug: Ga-68-PSMA-11
RxNorm normalized name: Ga-68 PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga-68-PSMA-11 is produced via a lyophilized Sterile Cold kit. Ga-68 is eluted from a Ge-68/Ga-68 generator into a vial containing the premixed peptide and buffer. PSMA-11 radiolabeled with Ga-68 is administered to patients following verification of standard quality controls including activity measurement, pH, radiochemical purity, and visual inspection
Trial: NCT05060666
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 doses of Ivermectin will be administered with 48 hours time interval.~The dosage is based on body weight calculated as follows:~* 15 mg for 40-60 kg = 5 tablets à 3 mg~* 18 mg for 60-80 kg = 6 tablets à 3 mg~* 24 mg for \> 80 kg = 8 tablets à 3 mg each~This corresponds to an ivermectin dose of about 300 µg / kg.
Trial: NCT00096837
Drug: Motexafin Gadolinium Injection
RxNorm normalized name: gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05841134
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, D1, Q3W, a total of 4 cycles; Oxaliplatin 130mg/m2, intravenous infusion, D1, Q3W, 4 cycles in total; Capecitabine 1000mg/m2, orally twice in the morning and evening, D1-14, Q3W, 4 cycles in total;~Adjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, Q3W;~± Chemotherapy method (researcher judges whether to add chemotherapy according to the comprehensive condition of the patient); Until disease progression or unacceptable toxicity, the maximum treatment time is 12 months.
Trial: NCT05304871
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: infusion
Trial: NCT05769842
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1\~2mg/kg before extubation when the patient recovered spontaneously.
Trial: NCT06336096
Drug: Suzetrigine
RxNorm normalized name: Suzetrigine
DrugBank: Suzetrigine (DB18927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) for oral administration.
Trial: NCT06336096
Drug: Suzetrigine
RxNorm normalized name: Suzetrigine
DrugBank: Suzetrigine (DB18927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) and Suspension for oral administration.
Trial: NCT05525767
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
Trial: NCT01797276
Drug: Dichloroacetate
RxNorm normalized name: Dichloroacetate
DrugBank: Dichloroacetic acid (DB08809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are given DCA 25mg/kg in a divided dose twice a day.
Trial: NCT00002288
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04543955
Drug: Telotristat (Low-Dose)
RxNorm normalized name: telotristat
DrugBank: Telotristat (DB14218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 750mg per day (250mg TID) for 20 months.
Trial: NCT04543955
Drug: Telotristat (High-Dose)
RxNorm normalized name: telotristat
DrugBank: Telotristat (DB14218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 1500mg per day (500mg TID) for 20 months.
Trial: NCT06448312
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Infusion
Trial: NCT05120622
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab 25 mg / 50 mg / 75 mg local cystoscopic injection into bladder wall at or adjacent to site of prior tumour resection (dose divided into 4 injection sites), administered 6 and 3 weeks before radical cystectomy.~Durvalumab 1500mg via IV infusion administered 6 and 3 weeks before radical cystectomy.
Trial: NCT06122428
Drug: modified hyaluronic acid 0.1% covalently linked to Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
Trial: NCT06122428
Drug: hyaluronic acid 0.1%
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
Trial: NCT05504148
Drug: crocin
RxNorm normalized name: CROCIN
DrugBank: Crocin (DB11874)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take saffron total glucosides tablets for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day.
Trial: NCT04778267
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
Trial: NCT04778267
Drug: Dexamethasone phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: used as additive to bupivacaine
Trial: NCT06085352
Drug: TetraLens bandage contact lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methafilcon-A contact lens eluding tetracaine ophthalmic solution
Trial: NCT04975373
Drug: Intrauterine injection of hyaluronic acid
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
Trial: NCT04937569
Drug: Ivermectin Tablets
RxNorm normalized name: Ivermectin Tablets
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-days course of Ivermectin 400 microgram/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast
Trial: NCT05369234
Drug: Carafate
RxNorm normalized name: Carafate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carafate taken as a slurry
Trial: NCT05132699
Drug: Cannabidiol (CBD) oral solution
RxNorm normalized name: cannabidiol (CBD) ORAL SOLUTION, ORAL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: An oral strawberry flavored liquid, taken as a 2.5ml (250mg) dose twice a day
Trial: NCT05997732
Drug: Phenylephrine Hydrochloride
RxNorm normalized name: Phenylephrine Hydrochloride
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.
Trial: NCT05997732
Drug: Isoproterenol Hydrochloride
RxNorm normalized name: Isoproterenol Hydrochloride
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.
Trial: NCT05997732
Drug: Norepinephrine Bitartrate
RxNorm normalized name: Norepinephrine Bitartrate
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.
Trial: NCT05997732
Drug: Propranolol Hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.
Trial: NCT05151328
Drug: Plecanatide
RxNorm normalized name: Plecanatide
DrugBank: Plecanatide (DB13170)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plecanatide or Placebo; Route of Plecanatide/placebo administration: tablet; dosage: 3mg, dosage form oral; Frequency of administration: QD
Trial: NCT05997732
Drug: Phentolamine Mesylate
RxNorm normalized name: Phentolamine Mesylate
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.
Trial: NCT05997732
Drug: Phenylephrine Hydrochloride
RxNorm normalized name: Phenylephrine Hydrochloride
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.
Trial: NCT05997732
Drug: Isoproterenol Hydrochloride
RxNorm normalized name: Isoproterenol Hydrochloride
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.
Trial: NCT05997732
Drug: Propranolol Hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.
Trial: NCT06451211
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200 mg will be administered systemically on day 1 of each cycle in all participants
Trial: NCT06451211
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 150 mg will be administered systemically on day 1 of each cycle in all participants
Trial: NCT06451211
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 40 mg will be administered orally on day 1-14 of each cycle in all participants
Trial: NCT05520138
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As provided in real-world setting
Trial: NCT05520138
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As provided in real-world setting
Trial: NCT01449357
Drug: zalutumumab
RxNorm normalized name: Zalutumumab
DrugBank: Zalutumumab (DB12202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, 16mg/kg on weekly basis until DP
Trial: NCT04575857
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.
Trial: NCT06478927
Drug: Palbociclib capsules
RxNorm normalized name: Palbociclib Capsules
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib capsules, oral, 125 mg/dose, qd, take 3 weeks and then stop for 1 week, 28d for one treatment cycle until disease progression or intolerable toxicity.
Trial: NCT05865548
Drug: Aspirin 150 mg
RxNorm normalized name: aspirin 150 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 150 mg PO daily
Trial: NCT04011163
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous medication used is morphine diluted in normal saline to a concentration of 1mg/ml. This is a standard dilution and are routine drugs used as standard of care.
Trial: NCT04811313
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients treated with TXA will have reduced blood loss and transfusion requirements compared with those who did not receive TXA
Trial: NCT06691906
Drug: Enlicitide decanoate
RxNorm normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT00002340
Drug: Atovaquone
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002340
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05167500
Drug: Lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: No treatment will be administered to the patient as an active treatment of this study. Only retrospective data about the patients treated in the compassion use program of Lorlatinib will be collected. The information below is related to Lorlatinib, target drug for the collection of data.~Lorviqua 25 mg film-coated tablets.The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. Dosing interruption or dose reduction may be required based on individual safety and tolerability.Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily.
Trial: NCT06110793
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20mg orally PO daily
Trial: NCT06110793
Drug: Pembrolizuma
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg IV Q6W
Trial: NCT06110793
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg IM Q4W
Trial: NCT05297422
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine
Trial: NCT05297422
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine
Trial: NCT05039580
Drug: PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.
Trial: NCT05271084
Drug: Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg
RxNorm normalized name: citalopram 20 MG
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties
Trial: NCT05271084
Drug: Citalopram (tablet) 20 mg + Placebo (tablet)
RxNorm normalized name: citalopram 20 MG
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI) + placebo
Trial: NCT02315157
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04695106
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months.
Trial: NCT04695106
Drug: Dabigatran Etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
Trial: NCT04695106
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
Trial: NCT04695106
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
Trial: NCT04898374
Drug: Gemcitabin/cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy combination
Trial: NCT04761887
Drug: Cool Ropivacaine Block
RxNorm normalized name: Ivy Block
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine is cooled.
Trial: NCT04761887
Drug: Room Temp Ropivacaine Block
RxNorm normalized name: Ivy Block
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Room Temp Block
Trial: NCT04719065
Drug: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.